Clinical trials: Molluscum Contagiosum
Molluscum Contagiosum
A Phase 3 Efficacy & Safety of SB206 & Vehicle Gel for the Treatment of MC
This is a Phase 3 multi-center, randomized, double-blind, vehicle-controlled, parallel group study to be conducted in up to approximately 340 subjects ≥6 months of age with MC.
- Trial name
- B-SIMPLE2 (NCT03927703)
- Testing
- SB206 12%
- Where
- 27 sites in United States
- Volunteers
- 355 people
- Sponsor
- Novan, Inc.
Molluscum Contagiosum
Safety and Efficacy of Topical Cantharidin for the Treatment of Molluscum Contagiosum, Phase 2
Cantharidin is cited in the dermatology and pediatric literature as a valuable treatment option. Treatment is often available in private practice offices, where a prescribing physician may offer a non-FDA approved treatment on an…
- Trial name
- NCT03017846
- Testing
- Cantharidin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Steven R Cohen
Molluscum Contagiosum
Cantharidin Application in Molluscum Patients
This study is a Phase 3, randomized, double-blind, placebo-controlled, pivotal study to evaluate the safety and efficacy of VP-102 topical film-forming solution in subjects with Molluscum Contagiosum.
- Trial name
- CAMP-2 (NCT03377803)
- Testing
- VP-102 - Cantharidin, Topical Film Forming Solution
- Where
- 15 sites in United States
- Volunteers
- 262 people
- Sponsor
- Verrica Pharmaceuticals Inc.
Molluscum Contagiosum, Skin Disease
Efficacy of Cantharidin in Molluscum Contagiosum
The University of North Carolina Department of Dermatology is conducting a clinical trial to evaluate a drug called cantharidin in the treatment of molluscum contagiosum.
- Trial name
- NCT00667225
- Testing
- cantharidin's vehicle, Cantharidin 0.7%
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of North Carolina, Chapel Hill
Molluscum Contagiosum
A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE1)
This is a Phase 3 multi-center, randomized, double-blind, vehicle-controlled, parallel group study to be conducted in up to approximately 340 subjects ≥6 months of age with MC.
- Trial name
- NCT03927716
- Testing
- SB206 12%
- Where
- 35 sites in United States
- Volunteers
- 352 people
- Sponsor
- Novan, Inc.
Molluscum Contagiosum
Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum.
The primary objective of the study is to determine the presence or absence of systemic cantharidin exposure from a single 24-hour dermal application of VP-102 topical film-forming solution [0.7% (w/v) cantharidin] (VP-102) when…
- Trial name
- NCT03186378
- Testing
- VP-102 with applicator
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Verrica Pharmaceuticals Inc.
Molluscum Contagiosum
A Study to Evaluate the Safety and Efficacy of SB206 in Subjects With Molluscum Contagiosum
This is a phase 2 multi-center, randomized, double-blind, vehicle-controlled ascending dose study to be conducted in non-immunocompromised subjects with molluscum contagiosum.
- Trial name
- NCT03436615
- Testing
- SB206 4%, SB206 8%, SB206 12%
- Where
- 18 sites in United States
- Volunteers
- 256 people, healthy volunteers welcome
- Sponsor
- Novan, Inc.
Molluscum Contagiosum
Cantharidin Application in Molluscum Patients-1
This study is a Phase 3, randomized, double-blind, placebo-controlled, pivotal study to evaluate the safety and efficacy of VP-102 topical film-forming solution in subjects with Molluscum Contagiosum.
- Trial name
- CAMP-1 (NCT03377790)
- Testing
- VP-102 - Cantharidin, Topical Film Forming Solution
- Where
- 18 sites in United States
- Volunteers
- 266 people
- Sponsor
- Verrica Pharmaceuticals Inc.
Verruca Vulgaris, Molluscum Contagiosum Skin Infection
Cold Atmospheric Plasma Device for Pediatric Molluscum and Verruca
This study is going to test a cold atmospheric plasma device (CAP), in particular a floating electrode-dielectric barrier device (FE-DBD), to treat warts and molluscum.
- Trial name
- NCT05070754
- Testing
- Floating electrode-dielectric barrier device (FE-DBD) cold atmospheric plasma (CAP), Cryotherapy, Canthardin Collodion
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Medical University of South Carolina
Molluscum Contagiosum
Safety and Efficacy Study of Topical Cantharidin for the Treatment of Molluscum Contagiosum
The purpose of this study is to determine if cantharidin is a safe and effective treatment for molluscum contagiosum in kids
- Trial name
- NCT02665260
- Testing
- Cantharidin, Gauze occlusion bandage
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Montefiore Medical Center
Molluscum Contagiosum
A Phase 3 Molluscum Contagiosum Efficacy and Safety Study
This is a phase 3 multi-center, randomized, double-blind, vehicle-controlled, parallel group study to be conducted in up to approximately 850 subjects 6 months of age and older with molluscum contagiosum (MC).
- Trial name
- B-SIMPLE4 (NCT04535531)
- Testing
- SB206 10.3% berdazimer, vehicle gel
- Where
- 55 sites in United States
- Volunteers
- 891 people
- Sponsor
- Novan, Inc.